FilingReader Intelligence
Marksans Pharma subsidiary gets US FDA omeprazole approval
August 8, 2025 at 05:29 AM UTC•By FilingReader AI
Marksans Pharma Inc., a subsidiary of Marksans Pharma Limited, received final USFDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC).
The product is bioequivalent to AstraZeneca's Prilosec Delayed-Release Tablets. Omeprazole is used for heartburn and acid-related conditions.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:MARKSANS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Marksans Pharma publishes news
Free account required • Unsubscribe anytime